Status: Recruiting
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
This is the first in human trial clinical study of AST-201 in patients with GPC3-positive advanced solid tumors. This study aims to evaluate the safety, tolerability, pharmacokinetic properties, and preliminary efficacy of AST-201 across various tumor types.
Participants needed: 70
Trial details
Phase: Phase 1Age: 19+Biological sex: AllType: InterventionalSponsor: Aptamer Sciences, Inc.Updated: Mar 27, 2026Locations: 4
Eligibility criteria
Male and female aged ≥19 years [+7]
Subjects with ischemic heart disease [+3]